SNDX news & sentiment — Syndax Pharmaceuticals Inc

MAY 3·Simply Wall StreetLow

Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives

Syndax Pharmaceuticals (SNDX) reported a narrowed Q1 2026 net loss of US$42.7 million on revenues of US$64.9 million, showing progress towards profitability. The company aims to shift from a 165.6% loss to a 14.7% profit margin in three years, despite a current trailing twelve-month loss of US$243.2 million. While bullish investors highlight strong forecast growth and a P/S discount compared to peers, bearish arguments focus on high R&D costs and dependence on a few lead drugs.

MAY 1·www.marketscreener.com

Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss

Syndax Pharmaceuticals (SNDX) reported a Q1 loss of $0.48 per share, which is better than FactSet's estimated loss of $0.61 per share. The company is a clinical-stage biopharmaceutical firm focused on developing cancer therapies, with product candidates including revumenib and axatilimab. They also reported Q1 revenue of $64.9 million, falling short of FactSet's estimate of $69.8 million.

MAY 1·Stock Titan

[8-K] Syndax Pharmaceuticals Inc Reports Material Event

Syndax Pharmaceuticals Inc. reported a significant increase in Q1 2026 revenue, reaching $64.9 million, a 224% year-over-year jump, primarily driven by strong launches of their drugs Revuforj and Niktimvo. Despite remaining loss-making, the company significantly narrowed its net loss to $42.7 million from $84.8 million a year prior. Syndax projects a path to profitability, anticipating its current cash, investments, and revenue streams will sufficiently cover operating expenses for 2026.

$SNDX

Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives

Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Loss $0.48, vs. FactSet Est of $0.61 Loss

[8-K] Syndax Pharmaceuticals Inc Reports Material Event

News on $SNDX